Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.
Van Cutsem E, Boni C, Tabernero J, Massuti B, Middleton G, Dane F, Reichardt P, Pimentel FL, Cohn A, Follana P, Clemens M, Zaniboni A, Moiseyenko V, Harrison M, Richards DA, Prenen H, Pernot S, Ecstein-Fraisse E, Hitier S, Rougier P. Van Cutsem E, et al. Among authors: ecstein fraisse e. Ann Oncol. 2015 Jan;26(1):149-156. doi: 10.1093/annonc/mdu496. Ann Oncol. 2015. PMID: 25416687 Free article. Clinical Trial.
Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme.
Heidenreich A, Scholz HJ, Rogenhofer S, Arsov C, Retz M, Müller SC, Albers P, Gschwend J, Wirth M, Steiner U, Miller K, Heinrich E, Trojan L, Volkmer B, Honecker F, Bokemeyer C, Keck B, Otremba B, Ecstein-Fraisse E, Pfister D. Heidenreich A, et al. Eur Urol. 2013 Jun;63(6):977-82. doi: 10.1016/j.eururo.2012.08.058. Epub 2012 Sep 3. Eur Urol. 2013. PMID: 23116658
Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy: Treatment Patterns From the PROXIMA Prospective Registry.
Akaza H, Procopio G, Pripatnanont C, Facchini G, Fava S, Wheatley D, Leung KC, Butt M, Silva A, Castillo L, Karavasilis V, Ӧzatılgan A, Hitier S, Ecstein-Fraisse EB, Ӧzgüroḡlu M. Akaza H, et al. Among authors: ecstein fraisse eb. J Glob Oncol. 2018 Sep;4:1-12. doi: 10.1200/JGO.18.00009. J Glob Oncol. 2018. PMID: 30260754 Free PMC article.
Impact of pegfilgrastim as primary prophylaxis for metastatic castration-resistant prostate cancer patients undergoing cabazitaxel treatment: an open-label study in Japan.
Kosaka T, Uemura H, Sumitomo M, Harada K, Sugimoto M, Hayashi N, Yoshimura K, Fukasawa S, Ecstein-Fraisse E, Sunaga Y, Oya M. Kosaka T, et al. Among authors: ecstein fraisse e. Jpn J Clin Oncol. 2019 Aug 1;49(8):766-771. doi: 10.1093/jjco/hyz051. Jpn J Clin Oncol. 2019. PMID: 31329922 Free PMC article. Clinical Trial.
Effect of Baseline Characteristics on Cabazitaxel Treatment Duration in Patients with Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the Compassionate Use/Expanded Access Programs and CAPRISTANA Registry.
Malik Z, Di Lorenzo G, Pichler A, De Giorgi U, Hitier S, Ecstein-Fraisse E, Ozatilgan A, Carles J. Malik Z, et al. Among authors: ecstein fraisse e. Cancers (Basel). 2020 Apr 17;12(4):995. doi: 10.3390/cancers12040995. Cancers (Basel). 2020. PMID: 32316580 Free PMC article.
14 results